3.170USD-3.35%Mkt Cap: —P/E: —1d ago
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and r…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value160.80M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.09M $
Revenue/Share—
Last Price3.170 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees34
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS0327973006
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.38
EPS (TTM)-0.58
EPS (Forward)—
52W Range
3.08028% of range3.400
52W High3.400 USD
52W Low3.080 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-30.79%
ROA-19.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF—
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-127.42M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio18.24
Quick Ratio18.18
Book Value/Sh1.313 USD
Cash/Share1.375 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.45.43M
Float89.79M
Insiders1.71%
Institutions40.63%
Technical
SMA 505.790 (-45.2%)
SMA 2007.240 (-56.2%)
Beta1.14
S&P 52W Chg20.80%
Avg Vol (30d)20.94K
Avg Vol (10d)3.92K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—